Affluent Medical Future Growth
Future criteria checks 0/6
Affluent Medical's revenue and earnings are forecast to decline at 46.3% and 33.4% per annum respectively while EPS is expected to decline by 1.7% per annum.
Key information
-33.4%
Earnings growth rate
-1.7%
EPS growth rate
| Medical Equipment earnings growth | 14.0% |
| Revenue growth rate | -46.3% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 27 Sep 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 1 | -31 | -30 | -29 | 2 |
| 12/31/2025 | N/A | -30 | -27 | -27 | 3 |
| 12/31/2024 | 3 | -13 | -10 | -10 | 3 |
| 6/30/2024 | 1 | -17 | -7 | -7 | N/A |
| 3/31/2024 | 1 | -16 | -10 | -10 | N/A |
| 12/31/2023 | 1 | -16 | -12 | -12 | N/A |
| 9/30/2023 | 1 | -15 | -13 | -13 | N/A |
| 6/30/2023 | 1 | -15 | -13 | -13 | N/A |
| 3/31/2023 | 1 | -15 | -12 | -12 | N/A |
| 12/31/2022 | 1 | -15 | -11 | -11 | N/A |
| 9/30/2022 | 1 | -15 | -12 | -12 | N/A |
| 6/30/2022 | 2 | -15 | -14 | -14 | N/A |
| 3/31/2022 | 2 | -15 | -13 | -13 | N/A |
| 12/31/2021 | 1 | -15 | -13 | -12 | N/A |
| 9/30/2021 | 1 | -15 | -11 | -10 | N/A |
| 6/30/2021 | 1 | -15 | -9 | -9 | N/A |
| 3/31/2021 | 1 | -15 | -9 | -9 | N/A |
| 12/31/2020 | 1 | -14 | -9 | -9 | N/A |
| 12/31/2019 | 1 | -17 | -12 | -11 | N/A |
| 12/31/2017 | 1 | -9 | N/A | -11 | N/A |
| 12/31/2016 | 1 | -6 | N/A | N/A | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AFME is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: AFME is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: AFME is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: AFME's revenue is expected to decline over the next 3 years (-46.3% per year).
High Growth Revenue: AFME's revenue is forecast to decline over the next 3 years (-46.3% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if AFME's Return on Equity is forecast to be high in 3 years time